KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non Operating Income: 2010-2024

Historic Other Non Operating Income for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Dec 2024 value amounting to -$8.2 million.

  • Jazz Pharmaceuticals' Other Non Operating Income rose 114.55% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 195.19%. This contributed to the annual value of -$8.2 million for FY2024, which is 193.11% down from last year.
  • Jazz Pharmaceuticals' Other Non Operating Income amounted to -$8.2 million in FY2024, which was down 193.11% from $8.8 million recorded in FY2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Other Non Operating Income peaked at $8.8 million during FY2023, and registered a low of -$19.0 million during FY2022.
  • Over the past 3 years, Jazz Pharmaceuticals' median Other Non Operating Income value was -$8.2 million (recorded in 2024), while the average stood at -$6.1 million.
  • In the last 5 years, Jazz Pharmaceuticals' Other Non Operating Income crashed by 337.10% in 2022 and then soared by 146.21% in 2023.
  • Yearly analysis of 5 years shows Jazz Pharmaceuticals' Other Non Operating Income stood at -$3.3 million in 2020, then crashed by 32.99% to -$4.3 million in 2021, then tumbled by 337.10% to -$19.0 million in 2022, then spiked by 146.21% to $8.8 million in 2023, then slumped by 193.11% to -$8.2 million in 2024.